1. Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial
- Author
-
Erica B. Bhavsar, Anthony R. Mato, Paul M. Barr, John M. Pagel, Ryan Jacobs, Chadi Nabhan, Jeffrey J. Pu, Joanna Rhodes, Nirav N. Shah, Clive S. Zent, Sasanka M. Handunnetti, Brian T. Hill, Alan P Skarbnik, Frederick Lansigan, Jakub Svoboda, John N. Allan, Chaitra S. Ujjani, Andre Goy, Hande H. Tuncer, Constantine S. Tam, Bruce D. Cheson, Stephen J. Schuster, Lindsey E. Roeker, Peter V. Pickens, Richard R. Furman, Danielle M. Brander, Alison R. Sehgal, Douglas F. Beach, Mazyar Shadman, and Nicole Lamanna
- Subjects
Male ,medicine.medical_specialty ,Population ,Article ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Piperidines ,Internal medicine ,medicine ,Humans ,education ,Survival analysis ,Aged ,Retrospective Studies ,Sequence Deletion ,Clinical Trials as Topic ,education.field_of_study ,business.industry ,Adenine ,Remission Induction ,Age Factors ,Retrospective cohort study ,Hematology ,Middle Aged ,Leukemia, Lymphocytic, Chronic, B-Cell ,Survival Analysis ,Rash ,Discontinuation ,Clinical trial ,Pyrimidines ,Treatment Outcome ,chemistry ,030220 oncology & carcinogenesis ,Ibrutinib ,Cohort ,Pyrazoles ,Female ,medicine.symptom ,business ,Chromosomes, Human, Pair 17 ,030215 immunology - Abstract
Ibrutinib demonstrated superior response rates and survival for treatment-naïve chronic lymphocytic leukemia (CLL) patients in a pivotal study that excluded patients younger than 65 (
- Published
- 2018